Structure-based virtual screening and optimization of modulators targeting Hsp90-Cdc37 interaction.

Identification of novel Hsp90 inhibitors to disrupt Hsp90-Cdc37 protein-protein interaction (PPI) could be an alternative strategy to achieve Hsp90 inhibition. In this paper, a series of small molecules targeting Hsp90-Cdc37 complex are addressed and characterized. The molecules' key characters are determined by utilizing a structure-based virtual screening workflow, derivatives synthesis, and biological evaluation. Structural optimization and structure-activity relationship (SAR) analysis were then carried out on the virtual hit of VS-8 with potent activity, which resulted in the discovery of compound 10 as a more potent regulator of Hsp90-Cdc37 interaction with a promising inhibitory effect (IC50 = 27 μM), a moderate binding capacity (KD = 40 μM) and a preferable antiproliferative activity against several cancer lines including MCF-7, SKBR3 and A549 cell lines (IC50 = 26 μM, 15 μM and 38 μM respectively). All the data suggest that compound 10 exhibits moderate inhibitory effect on Hsp90-Cdc37 and could be regard as a first evidence of a non-natural compound targeting Hsp90-Cdc37 PPI.

[1]  G. Chiosis,et al.  A global view of Hsp90 functions , 2013, Nature Structural &Molecular Biology.

[2]  K. Bhalla,et al.  Targeting HSP90 for cancer therapy , 2009, British Journal of Cancer.

[3]  L. Paz-Ares,et al.  Inhibition of HSP90 molecular chaperones: moving into the clinic. , 2013, The Lancet. Oncology.

[4]  Richard A. Lewis,et al.  Three-dimensional pharmacophore methods in drug discovery. , 2010, Journal of medicinal chemistry.

[5]  T. Tsuruo,et al.  Modulation of Akt kinase activity by binding to Hsp90. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[6]  S. Calderwood.  Molecular Cochaperones: Tumor Growth and Cancer Treatment , 2013, Scientifica.

[7]  Laurence H Pearl,et al.  Hsp90 and Cdc37 -- a chaperone cancer conspiracy. , 2005, Current opinion in genetics & development.

[8]  Tao Zhang,et al.  A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells , 2008, Molecular Cancer Therapeutics.

[9]  Abhinav Grover,et al.  Hsp90/Cdc37 Chaperone/co-chaperone complex, a novel junction anticancer target elucidated by the mode of action of herbal drug Withaferin A , 2011, BMC Bioinformatics.

[10]  R. Bhat,et al.  Progress in the discovery and development of heat shock protein 90 (Hsp90) inhibitors. , 2014, Journal of medicinal chemistry.

[11]  J. Buchner,et al.  Asymmetric activation of the hsp90 dimer by its cochaperone aha1. , 2010, Molecular cell.

[12]  Yong Jia.  Current status of HTRF® technology in kinase assays , 2008, Expert opinion on drug discovery.

[13]  Li Li,et al.  Optimization and bioevaluation of Cdc37-derived peptides: An insight into Hsp90-Cdc37 protein-protein interaction modulators. , 2017, Bioorganic & medicinal chemistry.

[14]  J. Harper,et al.  Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. , 1996, Genes & development.

[15]  S. Olesen,et al.  Stability of the Human Hsp90-p50Cdc37 Chaperone Complex against Nucleotides and Hsp90 Inhibitors, and the Influence of Phosphorylation by Casein Kinase 2 , 2015, Molecules.

[16]  M. Scaltriti,et al.  Molecular Pathways: Targeting Hsp90—Who Benefits and Who Does Not , 2012, Clinical Cancer Research.

[17]  Ming Zhao,et al.  Apigenin inhibits proliferation and induces apoptosis in human multiple myeloma cells through targeting the trinity of CK2, Cdc37 and Hsp90 , 2011, Molecular Cancer.

[18]  Hao-Ze Huang,et al.  Identification and optimization of novel Hsp90 inhibitors with tetrahydropyrido[4,3-d]pyrimidines core through shape-based screening. , 2014, European journal of medicinal chemistry.

[19]  P. Workman,et al.  Targeting CDC37: An alternative, kinase-directed strategy for disruption of oncogenic chaperoning , 2009, Cell cycle.

[20]  G. Giaccone,et al.  A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas , 2011, Clinical Cancer Research.

[21]  Min Zhang,et al.  FW-04-806 inhibits proliferation and induces apoptosis in human breast cancer cells by binding to N-terminus of Hsp90 and disrupting Hsp90-Cdc37 complex formation , 2014, Molecular Cancer.

[22]  L. Neckers,et al.  The double edge of the HSP90-CDC37 chaperone machinery: opposing determinants of kinase stability and activity. , 2012, Future oncology.

[23]  L. Whitesell,et al.  The stress response: implications for the clinical development of hsp90 inhibitors. , 2003, Current cancer drug targets.

[24]  G. Sethi,et al.  Molecular targets of celastrol derived from Thunder of God Vine: potential role in the treatment of inflammatory disorders and cancer. , 2011, Cancer letters.

[25]  L. Pearl,et al.  The Mechanism of Hsp90 Regulation by the Protein Kinase-Specific Cochaperone p50cdc37 , 2004, Cell.

[26]  Harald Schwalbe,et al.  The Human Cdc37·Hsp90 Complex Studied by Heteronuclear NMR Spectroscopy* , 2009, Journal of Biological Chemistry.

[27]  Tao Zhang,et al.  Characterization of Celastrol to Inhibit Hsp90 and Cdc37 Interaction* , 2009, The Journal of Biological Chemistry.

[28]  D. Altieri,et al.  COMPARTMENTALIZED CANCER DRUG DISCOVERY TARGETING MITOCHONDRIAL Hsp90 CHAPERONES , 2009, Oncogene.

[29]  Tony Taldone,et al.  Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. , 2012, Biochimica et biophysica acta.

[30]  Kate S. Carroll,et al.  Sulforaphane inhibits pancreatic cancer through disrupting Hsp90-p50(Cdc37) complex and direct interactions with amino acids residues of Hsp90. , 2012, The Journal of nutritional biochemistry.

[31]  L. Pearl,et al.  Hsp90-Dependent Activation of Protein Kinases Is Regulated by Chaperone-Targeted Dephosphorylation of Cdc37 , 2008, Molecular cell.

[32]  N. Rosen,et al.  Development of a Fluorescence Polarization Assay for the Molecular Chaperone Hsp90 , 2004, Journal of biomolecular screening.

[33]  C. Prodromou.  The ‘active life’ of Hsp90 complexes☆ , 2012, Biochimica et biophysica acta.

[34]  Lei Wang,et al.  Discovery and identification of Cdc37-derived peptides targeting the Hsp90–Cdc37 protein–protein interaction , 2015 .

[35]  J. Ulander,et al.  Ligand Binding Thermodynamics in Drug Discovery: Still a Hot Tip? , 2015, Journal of medicinal chemistry.

[36]  C. Ottmann,et al.  Modulators of protein-protein interactions. , 2014, Chemical reviews.